Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Abstract
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,048 severe disease cases and 571,009 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41×10-7). These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
Competing Interest Statement
See Suppl. Table 2.
Funding Statement
See Suppl. Tables 2-4.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
See Suppl. Table 1-2.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: See Suppl. Tables 2-4.
Disclosures: See Supp. Tables 2-4.
The author list was updated. William Lee was added as a co-author, and Urszula Korotko was moved up the authors list. No additional changes were made.
Data Availability
The exome-wide burden test summary statistics are available in the Supplements. The single variant association studies summary statistics will be made available openly on the GWAS Catalog.
Subject Area
- Addiction Medicine (381)
- Allergy and Immunology (699)
- Anesthesia (189)
- Cardiovascular Medicine (2832)
- Dermatology (242)
- Emergency Medicine (427)
- Epidemiology (12531)
- Forensic Medicine (10)
- Gastroenterology (800)
- Genetic and Genomic Medicine (4409)
- Geriatric Medicine (400)
- Health Economics (712)
- Health Informatics (2838)
- Health Policy (1045)
- Hematology (373)
- HIV/AIDS (893)
- Medical Education (412)
- Medical Ethics (114)
- Nephrology (460)
- Neurology (4167)
- Nursing (220)
- Nutrition (615)
- Oncology (2194)
- Ophthalmology (623)
- Orthopedics (254)
- Otolaryngology (316)
- Pain Medicine (265)
- Palliative Medicine (81)
- Pathology (485)
- Pediatrics (1169)
- Primary Care Research (481)
- Public and Global Health (6752)
- Radiology and Imaging (1484)
- Respiratory Medicine (897)
- Rheumatology (430)
- Sports Medicine (365)
- Surgery (471)
- Toxicology (57)
- Transplantation (200)
- Urology (173)